Wearing‐off scales in Parkinson's disease: Critique and recommendations
暂无分享,去创建一个
Angelo Antonini | Mark Stacy | Regina Katzenschlager | Anette Schrag | Werner Poewe | Cristina Sampaio | Fabrizio Stocchi | W. Poewe | G. Stebbins | M. Stacy | C. Goetz | R. Hauser | P. Martínez-Martín | C. Sampaio | A. Schrag | M. Merello | A. Antonini | R. Katzenschlager | F. Stocchi | P. Odin | O. Rascol | R. Chaudhuri | Marcelo Merello | Robert Hauser | Pablo Martinez‐Martin | Per Odin | Christopher G. Goetz | Oliver Rascol | Glenn T. Stebbins | Ray K. Chaudhuri
[1] Mark Stacy,et al. Identification of motor and nonmotor wearing‐off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment , 2005, Movement disorders : official journal of the Movement Disorder Society.
[2] M. Stacy. The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson’s disease , 2010, Journal of Neural Transmission.
[3] K. Dujardin,et al. Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations , 2008, Movement disorders : official journal of the Movement Disorder Society.
[4] R. M. Stewart,et al. The sensitivity and specificity of the 9-item Wearing-off Questionnaire. , 2008, Parkinsonism & related disorders.
[5] L. Lopiano,et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcome , 2007, Movement disorders : official journal of the Movement Disorder Society.
[6] S. Fahn. Unified Parkinson's Disease Rating Scale , 1987 .
[7] R. Hauser,et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations , 2008, Movement disorders : official journal of the Movement Disorder Society.
[8] E. Tolosa,et al. Validation of the “QUICK” questionnaire—A tool for diagnosis of “wearing‐off” in patients with Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.
[9] G. Stebbins,et al. Efficacy of a patient‐training videotape on motor fluctuations for on‐off diaries in parkinson's disease , 1997, Movement disorders : official journal of the Movement Disorder Society.
[10] K. Dujardin,et al. Anxiety rating scales in Parkinson's disease: Critique and recommendations , 2008, Movement disorders : official journal of the Movement Disorder Society.
[11] W. Oertel,et al. Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson’s disease patients with wearing-off: efficacy, safety and feasibility—an open-label, 6-week study , 2010, Journal of Neural Transmission.
[12] W Poewe,et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial , 2005, The Lancet.
[13] D. Nyholm,et al. Comparison of apomorphine and levodopa infusions in four patients with Parkinson’s disease with symptom fluctuations , 2009, Acta neurologica Scandinavica.
[14] J. Jankovic,et al. Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.
[15] J. Obeso,et al. When Do Levodopa Motor Fluctuations First Appear in Parkinson’s Disease? , 2010, European Neurology.
[16] The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations , 2003, Movement disorders : official journal of the Movement Disorder Society.
[17] M. Muenter,et al. Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.
[18] E. Tolosa,et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial , 2007, The Lancet Neurology.
[19] Carlo Colosimo,et al. Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations , 2010, Movement disorders : official journal of the Movement Disorder Society.
[20] W. Poewe,et al. Scales to assess psychosis in Parkinson's disease: Critique and recommendations , 2008, Movement disorders : official journal of the Movement Disorder Society.
[21] C. Marsden,et al. Recent Developments in Parkinson's Disease , 1986 .
[22] Y. Agid,et al. Stimulation of the subthalamic nucleus in Parkinson’s disease: a 5 year follow up , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[23] L. Seeberger,et al. A Home Diary to Assess Functional Status in Patients with Parkinson's Disease with Motor Fluctuations and Dyskinesia , 2000, Clinical neuropharmacology.
[24] K. Lyons,et al. Electronic motor function diary for patients with Parkinson's disease: a feasibility study. , 2007, Parkinsonism & related disorders.
[25] Stanley Fahn,et al. Does levodopa slow or hasten the rate of progression of Parkinson’s disease? , 2005, Journal of Neurology.
[26] William W. McDonald,et al. Depression rating scales in Parkinson's disease: Critique and recommendations , 2007, Movement disorders : official journal of the Movement Disorder Society.
[27] W. Poewe,et al. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[28] D. Nyholm,et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease , 2005, Neurology.
[29] G. Friehs,et al. Development and initial validation of a screening tool for Parkinson disease surgical candidates , 2004, Neurology.
[30] M. Stacy,et al. Development of a Patient Questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson’s disease , 2007, Journal of Neural Transmission.
[31] E. Tolosa,et al. The Patient Card Questionnaire to Identify Wearing-off in Parkinson Disease , 2007, Clinical neuropharmacology.
[32] F. Stocchi. The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations , 2006, Expert opinion on pharmacotherapy.
[33] O. Lindvall,et al. Use and interpretation of on/off diaries in Parkinson’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[34] R. Hauser,et al. Parkinson's disease home diary: Further validation and implications for clinical trials , 2004, Movement disorders : official journal of the Movement Disorder Society.
[35] A. M. de Noordhout,et al. Detection of motor and non-motor symptoms of end-of dose wearing-off in Parkinson's disease using a dedicated questionnaire: a Belgian multicenter survey. , 2006, Acta neurologica Belgica.
[36] M. Ceccaldi,et al. Nonmotor fluctuations in Parkinson’s disease: Frequent and disabling , 2002, Neurology.
[37] E. Tolosa,et al. End-of-dose Wearing Off in Parkinson Disease: A 9-Question Survey Assessment , 2006, Clinical neuropharmacology.
[38] A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. , 2005, Archives of neurology.
[39] P. Tuite,et al. Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005) , 2008, Annals of neurology.
[40] A. Bonnet,et al. [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.
[41] C. Tanner,et al. Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.